Henry Schein vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest dental/medical distributor; recovered from 2023 ALPHV ransomware attack; $12.4B 2024 revenue; digital dentistry platform driving recurring tech revenue.
About
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, founded in 1932 by Henry Schein in Queens, New York, and headquartered in Melville, New York. The company trades on Nasdaq (HSIC) and generated approximately $12.4 billion in net sales in 2024, serving over one million healthcare practitioners across more than 30 countries. Henry Schein operates through two segments: Health Care Distribution, supplying dental and medical consumables, equipment, and technology; and Technology and Value-Added Services, offering practice management software and digital dentistry solutions under brands like Dentrix, Dexis, and Axium.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.